中國創新投資(01217.HK):向心和龔青被要求配合調查 已聘請台灣律師提供協助
格隆匯11月25日丨中國創新投資(01217.HK)公佈,就近日出現有關公司、公司主席兼行政總裁向心參與所謂情報及特務活動的虛假新聞報道,於2019年11月25日,公司收到執行董事向心和替任董事龔青的通知,稱他們在台北桃園機場離境時,收到台灣法務部調查局桃園市調查處發出通知書,要求就該新聞報道事宜配合調查(“該配合調查”)。向心和龔青已聘請台灣律師提供協助。
事實上,向心和龔青對該新聞報道所曝事項根本無一所知,王立強從來不曾是集團的員工,該新聞報道所述事項全為虛構和偽造。
董事確認,公司一切業務和運營照常,有關該新聞報道及該配合調查將不會對公司的業務及營運構成任何重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.